The diagnostic sensitivity of CA-125 in ovarian cancer is related to the tumor stage, with abnormal CA-125 serum concentration seen in approximately 50% of patients with stage I disease and 80–90% of patients with stages III–IV disease (Nustad et al., 1996; Li et al., 2009). This evidence concerns the gene MUC16 and neoplasm.